GlaxoSmithKline plc (GLAXF)
- Motley Fool
Should GlaxoSmithKline Have Accepted Unilever's $68 Billion Consumer Health Offer?
In this Motley Fool Live video recorded on Jan. 19, Motley Fool contributors Keith Speights and Brian Orelli discuss whether they think GlaxoSmithKline should have accepted Unilever's offer. Keith Speights: One of the big stories in recent days was that GlaxoSmithKline (NYSE: GSK) revealed that it turned down an offer of more than $68 billion from Unilever (NYSE: UL) to buy the combined consumer health unit of Glaxo and Pfizer (NYSE: PFE).
- Zacks
Gilead's (GILD) Magrolimab Studies Put on Hold by the FDA
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
- Zacks
Glaxo's (GSK) New Drugs Drive Sales Amid Rising Competition
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
